Efficacy and safety of fasiglifam ( <scp>TAK</scp> ‐875), a <scp>G</scp> protein‐coupled receptor 40 agonist, in <scp>J</scp> apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase <scp>III</scp> trial

Abstract

Fasiglifam significantly improved glycaemic control and was well tolerated, with a low risk of hypoglycaemia in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise; however, in a recent review of data from overall fasiglifam global clinical trials, concerns about liver safety arose and the clinical development of fasiglifam was terminated after this trial was completed.